NEW OPTIONS OF USE OF PIPERIDINYLINDOLE DERIVATIVES Russian patent published in 2023 - IPC A61K31/454 A61P13/12 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the field of medicine, namely to the use of a compound of the formula (I) or its pharmaceutically acceptable salt in the treatment of factor B-mediated diseases selected from C3-glomerulopathy (hereinafter – C3G), IgA-nephropathy (hereinafter – IgAN), membranous nephropathy (hereinafter – MN), and hemolytic-uremic syndrome induced by E. coli (hereinafter – HUS),

where R is hydrogen, C₁-C₄alkyl, or C₁-C₆alkoxy; R¹ is C₁-C₆alkoxy; R² is C₁-C₆alkyl; R³ is C₁-C₆alkoxy, C₁-C₆alkyl, or hydroxyl; R⁴ is phenyl substituted with -H or -C(O)R⁸, and R⁸ is hydroxy, C₁-C₄alkoxy, C₁-C₄alkoxy, or amino. The invention also relates to a method for the treatment or prevention of factor B-mediated diseases selected from C3G, IgAN, MN, or HUS in a patient suffering from them, including administration to the specified patient of a daily dose selected from 25, 50, 100, and 200 mg twice a day of a compound of the formula (I) or its pharmaceutically acceptable salt. The invention also relates to the use of a pharmaceutical composition containing therapeutically effective amount of a compound of the formula (I) or its pharmaceutically acceptable salt and one or several pharmaceutically acceptable carriers in the treatment of factor B-mediated diseases selected from diseases or disorders selected from C3G, IgAN, MN, and HUS.

EFFECT: group of inventions provides development of a method for the treatment or prevention of factor B-mediated diseases, such as complement system-mediated kidney diseases C3G and IgAN, as well as other nephropathies with a sign of C3 deposition in glomeruli, such as MN and HUS.

13 cl